- Home
- TOYO vs ALDX Comparison
TOYO vs ALDX Comparison
Compare TOYO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- ALDX
- Stock Information
- Founded
- TOYO 2022
- ALDX 2004
- Country
- TOYO Japan
- ALDX United States
- Employees
- TOYO N/A
- ALDX N/A
- Industry
- TOYO
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- ALDX Health Care
- Exchange
- TOYO NYSE
- ALDX Nasdaq
- Market Cap
- TOYO 153.8M
- ALDX 160.8M
- IPO Year
- TOYO N/A
- ALDX 2014
- Fundamental
- Price
- TOYO $3.69
- ALDX $4.30
- Analyst Decision
- TOYO
- ALDX Strong Buy
- Analyst Count
- TOYO 0
- ALDX 2
- Target Price
- TOYO N/A
- ALDX $9.50
- AVG Volume (30 Days)
- TOYO 12.5K
- ALDX 1.0M
- Earning Date
- TOYO 08-21-2025
- ALDX 07-31-2025
- Dividend Yield
- TOYO N/A
- ALDX N/A
- EPS Growth
- TOYO 350.49
- ALDX N/A
- EPS
- TOYO 1.09
- ALDX N/A
- Revenue
- TOYO $176,957,128.00
- ALDX N/A
- Revenue This Year
- TOYO N/A
- ALDX N/A
- Revenue Next Year
- TOYO N/A
- ALDX N/A
- P/E Ratio
- TOYO $3.40
- ALDX N/A
- Revenue Growth
- TOYO 183.69
- ALDX N/A
- 52 Week Low
- TOYO $1.36
- ALDX $1.14
- 52 Week High
- TOYO $7.22
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- ALDX 78.08
- Support Level
- TOYO N/A
- ALDX $3.68
- Resistance Level
- TOYO N/A
- ALDX $4.21
- Average True Range (ATR)
- TOYO 0.00
- ALDX 0.28
- MACD
- TOYO 0.00
- ALDX 0.10
- Stochastic Oscillator
- TOYO 0.00
- ALDX 93.48
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries, is engaged in research and development, production, and sales of solar cells. Geographically, the company generates revenue from Asia and the USA, out of which the majority of revenue is generated from Asia.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.